Physician profile
Chad Conner
NPI 1669906392
$1,320.55
in general payments reported to CMS, 2019-2025
14 companies · $62.32 in 2025
The $62.32 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $317 · 2022: $32.91 · 2023: $700 · 2024: $208 · 2025: $62.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $644 · Education: $327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $643.76 |
| Education | $327.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $341.92 | 2023-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Astrazeneca Pharmaceuticals Lp | $251.60 | 2021-2024 | Wainua, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $145.24 | 2023-2025 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $116.01 | 2021-2023 | Lifevest |
| Novartis Pharmaceuticals Corporation | $93.20 | 2023 | |
| Pfizer INC. | $84.85 | 2023 | |
| Astellas Pharma US INC | $79.99 | 2021 | |
| Novo Nordisk INC | $71.59 | 2024-2025 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.93 | 2023-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $23.15 | 2023 | Xarelto |
| Medtronic, INC. | $19.94 | 2022 | |
| Lantheus Medical Imaging, INC. | $17.39 | 2023 | Definity |
| Esperion Therapeutics, INC. | $16.72 | 2024 | Nexletol |
| Biomerieux INC | $15.02 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Conner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.